Biopharma dealmaking hit $35.07 billion in June 2025, marking the highest monthly total this year and contributing to a $138.31 billion first-half total surpassing previous years' full totals. This robust activity highlights sustained investor confidence and sector dynamism amid evolving pipelines and market conditions. Notable transactions include acquisitions, financings, and partnerships strengthening R&D and commercial strategies.